Andrew Hahn discusses the LenCabo study, a randomized phase 2 trial comparing lenvatinib plus everolimus versus cabozantinib for metastatic clear cell renal cell carcinoma progressing on PD-1 ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Jacob Moyer and Mark Tyson present retrospective data on prophylactic rectal diazepam for intravesical nadofaragene firadenovec administration. Results demonstrate significant reductions in bladder ...
UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.
Read the Full Video Transcript Andrea Miyahira: Hi, everyone. I'm Andrea Miyahira with the Prostate Cancer Foundation. Thank you for joining me for a special Women in Science episode. And joining me ...
At the 2025 UCSF-UCLA PSMA Conference, Alfred Morgenstern discusses his work with actinium-PSMA therapy for prostate cancer. He reviews clinical programs including Mike Sathekge's work with ...
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
At the 2025 UCSF-UCLA PSMA Conference, Irène Buvat discusses how AI can simplify personalized dosimetry in radiopharmaceutical therapy, addressing the "catch-22" where complexity limits clinical use ...
At the 2025 UCSF-UCLA PSMA Conference, Emmanuel Antonarakis compares PSMA radioligand therapy trials in mCRPC for the post-ARPI, pre-chemotherapy setting. He examines PSMAfore (177Lu-PSMA-617), SPLASH ...
At the 2025 UCSF-UCLA PSMA Conference, EmmanuelAntonarakis reviews US guidelines for PSMA-PET in prostate cancer from NCCN, SNMMI, and AUA/SUO. He notes consensus on use for biochemical recurrence and ...
Read the Full Video Transcript Neeraj Agarwal: Welcome to another UroToday episode. Here we have Dr. Umang Swami, who is a faculty in oncology division at the Huntsman Cancer Institute at the ...
Zachary Klaassen hosts Javier Puente to discuss the PARASEC trial. Dr. Puente describes this retrospective observational study examining treatment patterns of patients who received darolutamide in the ...
Oliver Sartor hosts Michael Schweizer to discuss mevrometostat. Dr. Schweizer explains this EZH2 inhibitor targets lineage plasticity and regulates androgen receptor activity, potentially overcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback